^
BIOMARKER:

CDKN2A deletion

i
Other names: CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Entrez ID:
Related biomarkers:
CDKN2A deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
CDKN2A deletion
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
CDKN2A deletion
ALL
blinatumomab
Sensitive: C3 – Early Trials
CDKN2A deletion
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A deletion
Gallbladder Cancer
palbociclib
Resistant: C3 – Early Trials
CDKN2A deletion
Glioma
vincristine + lomustine + procarbazine hydrochloride
Resistant: C3 – Early Trials
CDKN2A deletion
HCC
Immunotherapy
Sensitive: C3 – Early Trials
CDKN2A deletion
Melanoma
palbociclib
Sensitive: C3 – Early Trials
CDKN2A deletion
Pancreatic Cancer
palbociclib
Resistant: C3 – Early Trials
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
CDKN2A deletion
Diffuse Large B Cell Lymphoma
T-lymphocyte cell therapy
Resistant: C3 – Early Trials
CDKN2A deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
palbociclib + SNS-510
Sensitive: D – Preclinical
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
ribociclib + SNS-510
Sensitive: D – Preclinical
CDKN2A deletion
Ewing Sarcoma
ASP7487
Sensitive: D – Preclinical
CDKN2A deletion
Ewing Sarcoma
palbociclib
Sensitive: D – Preclinical
CDKN2A deletion
RCC
temsirolimus
Sensitive: D – Preclinical